ARS Pharmaceuticals (SPRY) Cash from Operations (2020 - 2026)

ARS Pharmaceuticals has disclosed Cash from Operations across 7 years of filings, most recently posting 44946000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 44946000.0, down 10.32% year-over-year; the trailing twelve-month figure through Mar 2026 was 175070000.0 (down 754.67% YoY), and the FY2025 annual result was 170866000.0, down 1361.19% from the prior year.
• Cash from Operations came in at 44946000.0 for Q1 2026 at ARS Pharmaceuticals, down from 43485000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 42004000.0 in Q4 2024 to a low of 47047000.0 in Q3 2025.
• The 5-year median for Cash from Operations is 14467000.0 (2024), against an average of 17741647.06.
• Across the five-year window, Cash from Operations soared 341.33% in 2024 and sank 507.18% in 2025, its largest moves.
• ARS Pharmaceuticals' Cash from Operations stood at 20497000.0 in 2022, then grew by 15.09% to 17405000.0 in 2023, then jumped by 341.33% to 42004000.0 in 2024, then plunged by 203.53% to 43485000.0 in 2025, then slipped by 3.36% to 44946000.0 in 2026.
• The last three Cash from Operations figures came in at 44946000.0 (Q1 2026), 43485000.0 (Q4 2025), and 47047000.0 (Q3 2025), per Business Quant data.